Dr. Charles Theuer, MD, PhD

Chief Medical Officer, Halozyme Inc.

Dr. Charles Theuer is Chief Medical Officer of Halozyme. He previously led TRACON Pharmaceuticals as President and CEO from 2006. At Pfizer he led clinical development of the kidney-cancer drug Sutent, and at TargeGen he started the program behind Inrebic, now approved for myelofibrosis. A board-certified general surgeon, he holds a BS from MIT, an MD from UCSF and a PhD in Epidemiology from UC Irvine.